ArticleClinical and experimental medicine2025
CCL22 as a diagnostic and prognostic biomarker for pediatric-onset systemic lupus erythematosus.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management of systemic lupus erythematosus and antiphospholipid syndrome during CAR-T therapy: insights from two clinical cases.Immuno-oncology technology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSystemic lupus erythematosus (SLE) is an autoimmune disease characterized by diverse symptoms and multisystem involvement. Pediatric-onset systemic lupus erythematosus (pSLE) accounts for 10-20% of all SLE cases and tends to progress more rapidly and severely than adult-onset SLE, making diagnosis more challenging. Current biomarkers remain insufficient in predicting disease severity and organ-specific complications, highlighting the need for new biomarkers.
methodsThis study included 36 pSLE patients and 18 age and gender matched healthy controls. Serum CCL22 levels were measured by luminex immunoassay. Correlations between CCL22, disease activity (SLEDAI), and 40 laboratory indicators were analyzed using Pearson correlation. Receiver operating characteristic curve analysis was used to evaluate the diagnostic value of CCL22 for pSLE and its association with system involvement.
resultsResults showed significantly lower serum CCL22 in pSLE patients compared to controls (P < 0.0001), negatively correlating with SLEDAI scores (r = -0.3951, P < 0.05). CCL22 demonstrated strong diagnostic potential (AUC = 0.8704, 95% CI: 0.778-0.963, P < 0.0001) with an optimal cutoff value of 145.86 pg/mL. Patients with low CCL22 (CCL22 -) more often had lupus nephritis and pulmonary involvement, with significant renal dysfunction and inflammatory state, while those with higher CCL22 (CCL22 +) exhibited musculoskeletal involvement and elevated alkaline phosphatase levels, suggesting potential bone metabolism abnormalities.
conclusionCCL22 is a promising diagnostic biomarker for pSLE. Its expression levels are closely associated with renal, pulmonary, and musculoskeletal involvement, providing valuable insights for clinical intervention of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.